Compare TPVG & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPVG | ORMP |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.9M | 197.6M |
| IPO Year | 2013 | 2010 |
| Metric | TPVG | ORMP |
|---|---|---|
| Price | $4.39 | $4.07 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.83 | N/A |
| AVG Volume (30 Days) | ★ 187.3K | 137.1K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | ★ 20.81% | 6.14% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | 0.43 | ★ 2.76 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.96 | N/A |
| P/E Ratio | $10.28 | ★ $1.47 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $4.39 | $2.09 |
| 52 Week High | $6.95 | $5.47 |
| Indicator | TPVG | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 28.19 | 30.54 |
| Support Level | N/A | $3.91 |
| Resistance Level | $4.96 | $4.22 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 5.56 | 18.07 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.